![]() |
|
|
Vol. 303, Issue 2, 695-703, November 2002
Division on Substance Abuse, New York State Psychiatric Institute
and Department of Psychiatry, College of Physicians and Surgeons of
Columbia University, New York, New York
Buprenorphine is a partial µ-opioid agonist and
-opioid antagonist
currently under development as a maintenance medication for heroin
dependence. Because of concerns about illicit diversion of
buprenorphine, a combination tablet containing buprenorphine and
naloxone has been developed. The present study evaluated the reinforcing effects of intravenously administered placebo,
buprenorphine alone (BUP; 2 and 8 mg), and the buprenorphine/naloxone
combination (BUP/NX; 2 mg of buprenorphine plus 0.5 mg of naloxone, and
8 mg of buprenorphine plus 2 mg of naloxone) in recently detoxified heroin abusers during a 6-week inpatient study. Participants
(n = 6) were detoxified from heroin over
approximately 1 week immediately after admission. During the next 5 weeks, the reinforcing effects of placebo, BUP, and BUP/NX were
evaluated. Participants first received a dose of drug and $20 and then
were given the opportunity to self-administer either the dose or $20
during choice sessions. Progressive ratio break point values were
significantly higher after active drug, compared with placebo, but they
did not significantly differ as a function of dose or drug. In
contrast, positive subjective ratings were higher after administration
of BUP compared with BUP/NX, and these ratings increased in a
dose-dependent manner. BUP and the combination had few effects on
performance. Relative to placebo, both BUP and BUP/NX decreased pupil
diameter, but there were no significant differences in pupil diameter
as a function of drug or dose. These results demonstrate that both BUP
and BUP/NX served as reinforcers under these conditions and that they
may have similar abuse liability in recently detoxified individuals who
abuse heroin.
This article has been cited by other articles:
![]() |
S. D. Comer, M. A. Sullivan, and E. A. Walker Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1320 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Schottenfeld, M. C. Chawarski, J. R. Pakes, M. V. Pantalon, K. M. Carroll, and T. R. Kosten Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence Am J Psychiatry, February 1, 2005; 162(2): 340 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Sell, L. R. McMahon, and C. P. France Relative Efficacy of Buprenorphine, Nalbuphine and Morphine in Opioid-Treated Rhesus Monkeys Discriminating Naltrexone J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1167 - 1173. [Abstract] [Full Text] [PDF] |
||||